Delivery Order SPE2DB22D3016-SPE2DB25FBHT3
Award Date 9/9/25
Potential Completion Date 9/10/25
Potential Value $6.8K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $8,424.80 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 2, 2025, with completion expected by September 3, 2025. This delivery order represents a firm fixed-price contract with no set-aside designation, awarded through competitive procurement. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for...
- The Defense Logistics Agency (DLA) awarded a $273,806 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 9, 2025, with completion expected by September 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing...
- The Defense Logistics Agency awarded a $120,474.64 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 25, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing part of the Defense...
- The Defense Logistics Agency awarded a delivery order valued at $2,106.20 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults aged 18 and older, and this...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes valued at $7,333.24 on September 8, 2025, with completion expected by September 9, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults 18 years of age and older, representing a...
- The Defense Logistics Agency awarded a delivery order valued at $113,419 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 12, 2025, with completion targeted for August 13, 2025. This non-set-aside contract employs firm fixed pricing and represents a direct order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. HEPLISAV-B is a recombinant hepatitis B vaccine utilized by the Department of Defense for immunization programs...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for HEPLISAV-B 20 MCG/0.5 ML syringes with a ceiling value of $2,692.12. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 15, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults aged...
- The Defense Logistics Agency awarded a $6,318.60 delivery order to AmerisourceBergen Drug Corp for the supply of HEPLISAV-B 20 mcg/0.5 ml syringes on July 29, 2025. This firm fixed-price, non-set-aside contract is scheduled for completion by July 30, 2025, with performance executed from the contractor's location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention of hepatitis B virus infection in adults. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $8,424.80 to AmerisourceBergen Drug Corp on August 4, 2025, for HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed-price delivery order with an ultimate completion date of August 5, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was competitively awarded. HEPLISAV-B is a recombinant hepatitis B vaccine commonly procured by...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $134,719.00 on August 27, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 28, 2025. The product will be delivered to AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite...